Everlab to advance preventive health model with AI-driven health intelligence and advanced diagnostics at its core.
Australian preventive health clinic provider Everlab has secured US$10 million (AU$15 million) in seed funding to accelerate the rollout of its AI-driven approach to healthcare. The Melbourne-based company says the funding will support further development and international expansion of its preventive health platform, which is designed to deliver personalized, proactive care at scale.
Everlab’s model combines advanced diagnostics with AI-driven analysis and “digital-first” consultations with physicians. The clinic offers comprehensive screening services, including whole-body MRI scans, DEXA bone density scans, VO₂ max testing, ECG, isometric strength assessments, continuous glucose monitoring, CT coronary angiograms, food journal analysis and extensive blood testing. Findings are coupled with ongoing clinical support and personalized prevention plans designed to manage risk and improve health over time.
“At Everlab, we’re redefining healthcare as something proactive, personalised, and measurable,” the company’s Chief Medical Officer Dr Steven Lu told us. “Rather than waiting for illness, we use AI-driven health intelligence and advanced diagnostics to identify risks, blind spots, and opportunities – helping our members optimise their healthspan and longevity at every stage of life. Through continual data monitoring, personalisation, and a focus on outcomes, Everlab delivers a smarter, more adaptive approach to healthcare that builds trust, empowers people, and drives long-term results.”
At the heart of Everlab’s platform is its proprietary clinical infrastructure. AI agents ingest and interpret vast amounts of health data, generating automated clinical summaries, identifying risk factors early, and recommending tailored interventions. The result is a system designed not only to detect potential health issues earlier but also to support ongoing, data-driven management of risk and wellness.
“We believe everyone deserves access to world-class preventive care,” said Everlab CEO Marc Hermann. “By combining AI with the knowledge of leading clinicians, we’ve built a new kind of health platform designed to deliver smarter, earlier care to millions.”
Boasting a waitlist in the “tens of thousands,” Everlab claims it is seeing strong growth across both consumer and enterprise markets, with projections of twentyfold expansion this year. Services are delivered through a tiered membership structure, which ranges from blood biomarker testing packages priced at AU$499 up to more comprehensive longevity services costing AU$2,999 per year.
In a recent analysis of its first 1,000 members, over one million biomarkers were processed, with one in four readings outside optimal ranges and 2.5% uncovering urgent or serious health issues, including blocked arteries, early-stage cancers, autoimmune disorders and congenital brain abnormalities. These were often identified in individuals who felt healthy and would not otherwise have undergone such detailed testing.
Everlab’s diagnostic process looks across more than 100 biomarkers spanning cardiovascular, metabolic, hormonal, inflammatory, toxicological and performance domains. Common early warnings included elevated cardiovascular risk factors such as ApoB, triglycerides and Lp(a), metabolic indicators like insulin resistance and impaired glycaemic control, signs of chronic inflammation such as elevated hsCRP and homocysteine, and higher-than-expected toxin burdens in certain occupational and geographic groups. While these findings do not always signal immediate illness, they highlight underlying physiological stress that may progress into chronic disease if left unaddressed.
“Early detection doesn’t just save lives,” said Lu in a blog post about the results. “It gives people the time and space to act before a crisis hits. It opens a path for prevention rather than reaction.”
The new funding round, led by global growth equity firm Left Lane Capital, will allow Everland to extend its clinic network and further develop its AI-powered infrastructure, laying the groundwork for a scalable system designed to make early detection and precision prevention accessible to more people.
“Preventive care has always been a medical ideal but rarely a commercial reality,” said Left Lane’s Laura Sillman. “Everlab has built a product and model that makes it scalable, combining clinical depth with software leverage and operational precision.”
